Neurodegenerative diseases are characterized by progressive nervous system dysfunction, which affects over 90,000 people every year. Although numerous contrast agents and therapeutic drugs are available for the diagno...Neurodegenerative diseases are characterized by progressive nervous system dysfunction, which affects over 90,000 people every year. Although numerous contrast agents and therapeutic drugs are available for the diagnosis and therapy of neurodegenerative diseases, there are several limitations to their application. Particularly, these contrast agents and drugs are restricted from entering into the brain because of the blood-brain barrier, which represents a major bottleneck to efficacious and safe theranostics of neurodegenerative diseases. Nanoparticles can offer impressive improvement in the theranostics of neurodegenerative diseases, as they can effectively deliver contrast agents and drugs to target sites in the central nervous system. In this review, we describe various delivery systems, including lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and exosomes useful for the theranostics of neurodegenerative diseases. Finally, we outline current challenges and our perspectives on the development of delivery systems for theranostics of neurodegenerative diseases.展开更多
Ovarian cancer(OC)is a lethal threat to females.According to the 2022 Global Cancer Observatory(GLOBOCAN),new cases of OC were estimated to reach 324,398,with mortality figures at 206,839.China,with one-fifth of the w...Ovarian cancer(OC)is a lethal threat to females.According to the 2022 Global Cancer Observatory(GLOBOCAN),new cases of OC were estimated to reach 324,398,with mortality figures at 206,839.China,with one-fifth of the world population,is bearing a heavy OC health burden,accounting for 18.82%of all OC new cases and 15.8%of OC-related deaths worldwide.The OC incidence and mortality in China increased by 6.3%and 20%in the time intervals from 2016 to 2022,with a significant disparity between urban and rural areas in China[Supplementary Figure 1A,http://links.lww.com/CM9/C570].The new cases and deaths will reach 70,822 and 46,845 by 2050,respectively[Supplementary Figure 1B,http://links.lww.com/CM9/C570].Moreover,females are more susceptible to OC at ages above 50 years[Supplementary Figures 1C and D,http://links.lww.com/CM9/C570].Notably,nearly 50–70%of OC patients suffer from disease recurrence and will ultimately develop platinum resistance,causing over 90%of deaths with a median survival of less than 12 months.展开更多
基金This work was financially supported by the National High Technology Research and Development Program （No. 2016YFA0200303）, the Beijing Natural Science Foundation （No. L172046）, the National Natural Science Foundation of China （Nos. 31522023, 51373177, and 51573188）, the Beijing Municipal Science ＆ Technology Commission （No. Z161100002616015）, and the ＂Strategic Priority Research Program Research Program＂ of the Chinese Academy of Sciences （No. XDA09030301-3）.
文摘Neurodegenerative diseases are characterized by progressive nervous system dysfunction, which affects over 90,000 people every year. Although numerous contrast agents and therapeutic drugs are available for the diagnosis and therapy of neurodegenerative diseases, there are several limitations to their application. Particularly, these contrast agents and drugs are restricted from entering into the brain because of the blood-brain barrier, which represents a major bottleneck to efficacious and safe theranostics of neurodegenerative diseases. Nanoparticles can offer impressive improvement in the theranostics of neurodegenerative diseases, as they can effectively deliver contrast agents and drugs to target sites in the central nervous system. In this review, we describe various delivery systems, including lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and exosomes useful for the theranostics of neurodegenerative diseases. Finally, we outline current challenges and our perspectives on the development of delivery systems for theranostics of neurodegenerative diseases.
基金supported by grants from the National Natural Science Foundation of China(No.82374081)the Natural Science Foundation of Fujian Province(No.2023J011257).
文摘Ovarian cancer(OC)is a lethal threat to females.According to the 2022 Global Cancer Observatory(GLOBOCAN),new cases of OC were estimated to reach 324,398,with mortality figures at 206,839.China,with one-fifth of the world population,is bearing a heavy OC health burden,accounting for 18.82%of all OC new cases and 15.8%of OC-related deaths worldwide.The OC incidence and mortality in China increased by 6.3%and 20%in the time intervals from 2016 to 2022,with a significant disparity between urban and rural areas in China[Supplementary Figure 1A,http://links.lww.com/CM9/C570].The new cases and deaths will reach 70,822 and 46,845 by 2050,respectively[Supplementary Figure 1B,http://links.lww.com/CM9/C570].Moreover,females are more susceptible to OC at ages above 50 years[Supplementary Figures 1C and D,http://links.lww.com/CM9/C570].Notably,nearly 50–70%of OC patients suffer from disease recurrence and will ultimately develop platinum resistance,causing over 90%of deaths with a median survival of less than 12 months.
